Randomized Open-label Multicenter Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na ve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locally Advanced Or Metastatic Tyrosine Kinase Inhibitor (tki)-naïve Ros1-positive Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patient has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC
    2. Patient has a ROS1 gene rearrangement/fusion as detected by a local test
    3. Patients must not be exposed previously to TKIs that demonstrated activities in ROS1-positive NSCLC (eg, crizotinib, ceritinib, lorlatinib, brigatinib, entrectinib, ensartinib, DS6051b, NVL-520, taletrectinib, foretinib, and cabozantinib)

You may not be eligible for this study if the following are true:

    1. Symptomatic brain metastases or symptomatic leptomeningeal involvement
    2. History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected
    3. Known tumor targetable co-mutations or rearrangements (ie, epidermal growth factorreceptor [EGFR] or ALK)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.